weekly_roundup

BioTechSign Daily Catalyst Roundup - November 16, 2026

Top BioTechSign catalyst names today: BHVN, INO, EYPT, ADCT, SMMT, MLTX. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 16, 2026

Daily Biotech Catalyst Digest: November 16, 2026

BHVN leads the current BioTechSign screen at 84.9/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
BHVNBiohaven Ltd.84.9Apublication signal 100%, clinical activity 100%, dilution risk 50%
INOInovio Pharmaceuticals, Inc.84.5Apublication signal 100%, dilution risk 89%, short interest 70%
EYPTEyePoint, Inc.84.2Aclinical activity 100%, short interest 70%, dilution risk 43%
ADCTADC Therapeutics SA83.3Apublication signal 100%, clinical activity 100%, dilution risk 50%
SMMTSummit Therapeutics Inc.82.7Apublication signal 100%, clinical activity 100%, short interest 90%
MLTXMoonLake Immunotherapeutics82.2Aclinical activity 100%, short interest 70%, publication signal 35%

Recent Grade-Change Queue

  • XENE (Xenon Pharmaceuticals) currently grades D with a 40.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 46%, short interest 30%.
  • NVS (Novartis AG) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
  • FULC (Fulcrum Therapeutics) currently grades F with a 16.2/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 49%.
  • INBX (Inhibrx Inc) currently grades D with a 42.0/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 51%.
  • VTVT (vTv Therapeutics Inc.) currently grades D with a 35.4/100 catalyst score. Main inputs: clinical activity 38%, dilution risk 31%, short interest 30%.
  • TLSA (Tiziana Life Sciences Ltd.) currently grades D with a 48.2/100 catalyst score. Main inputs: dilution risk 59%, clinical activity 50%, publication signal 15%.
  • PASG (Passage Bio) currently grades D with a 42.3/100 catalyst score. Main inputs: publication signal 65%, dilution risk 53%, short interest 10%.
  • RNA (Atrium Therapeutics, Inc.) currently grades F with a 26.2/100 catalyst score. Main inputs: short interest 70%, dilution risk 41%, clinical activity 17%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.